(LADA) : !" "!#$ % & '() " * +$,$ Downloaded from ijdld.tums.ac.ir at 1:57 IRST on Thursday January 10th Latent Autoimmune Diabetes in Adults

Transcription

1 $%#$ :( ).!" " (LADA)!#$ % & '() " * +$,$ * () #* "!) +,- $%&!'!" # 6(7 68 ( #'(9 Glutamic Acid Decarboxylase 65 Latent Autoimmune Diabetes in Adults (GAD) (LADA) : #( 4 (!('&5 % 23 1 ). /01 ( ( LADA %() <(,- (= #( #%1.9 #'9 &!&) :%& $9 # &. B1 C? LADA $% 9 #7 #?:>)!('&5 F& B1 E : 8 #?:>) C #,'D) 23 1 ) # 4*!?>=)! : N (=1 L $%(& C J& HHM LADA J& 2L " #! CK1 J& HII C?.&9 G)5 GAD.&" #=) OP &9 C( LADA ".% %H/SS(CI%XH:%2/MW%U/2) LADA $% 9 HS/L±/M! O& ) : (![ 8!:%' %\ 0 C!" %&\ #= C N7,!& %1 #& Z F& L $%&!:() _ (.%( LADA '0( ^ $%(& C "!:%' %\ 0.&% P ] $% 9 %\.C9 &!%4>) )5 <8 GAD!'&5 ` 9 CDa) '! G!O0()5! :( (#(' ](* ( C! %\ &!' b: %H/S : (1 (9!(=>)!) (8!& GAD!'&5 GA #d!) F. & % B&5 O:c P).&%9!9 1 & f g&!& C # 1e ' #d C $% 9. /01 GAD LADA :!'0B O0& N :%') c <= =K1 *) - %&' ()*+, - -. /*01!" #$ :3454 * fhospanah@erc.ac.ir :!?) ;=>76>>2=>245 : ; =>7685=8>>2= ::0$ ; ),-/*/)* :& '(,-/2/01 :./ '(

2 ... 6A 3BC 6<D ><? 34& :9: ;678 $$,'D)!:%D8 68 # G* t 11!B.[2] "./0) # : O:c LADA # J' (!? ( ( C (B ( l, (1 C ( a*.9 f' 68!' # #* 9 #'9!#' ( ( (BMI) u& %1 #& 6a)!4) % ==K) 6(8 % C. /01 ) (( (( C(( #=(( (( & ((F1 (() #((%1 & * J' O' %\ <%(%* <(?:>) t(4c 6() % ( [ p[s] (& %(D& <J') L $%& C LADA " v.[mh] %() j%:% )( <,- #&%" = # #%1 LADA $% (9 #(7 #?:>) LADA B1 E : 8 #?:>) B1 B9 5 #(,'( w%)!:' >\ 6) %?1 &.9 (Longitudinal)!:%- #?:>) ] B1 E : 8 #?:>) ( (B1 +(9) B1 2 #=>) 2UU #* C %(!(?>=) #(?:>) x #* 5.C 9 ( C( #) 2I3 %B9 1 2UU J C #) 2/H <) # 9 $9 2I3 ) B).C( ( #?:>) )% %*1 2IS 1i( ( #( ( # 4d #?:>) m #?) ( "#(&%& l #( #(* %( (B1 2 #(=>) d( (d Cd(9 C(??1.&9 h/'& #9%\ 0(') '0( #(?:>) ( < 7.% J& H33H #?:>).[U] C 9 #(* C( 0()!?>=) #?:>) q y =K1 # ]! G # 4*.( "!() (TLGS) B1 E : 8 #?:>) #&" 2IM (B (1 %(%) o('& %) %XH ( - t(q '9 F&.C 9 J' (?1 %3 $% 9 z 3/3LH >\ a* ((((((?).(9 (?1 (J& HH2 & %) #&%& 6* "!) +,- $%&!'!" # LADA!('&5 %( 23 G B&5. /01 ) #* Glutamic Acid Decarboxylase 65 (GAD 65 ) #( 4 ( #( ( & (. /0(1 () M 68 #'9 5 (.[] (9 #'9 &!&) :%& e $9 O & )& * ] $%& C 6='() (& ]( $%(& C LADA #* &=' C(:\!( N'( ( #(* (9!() (O ( & * h/'& /H #(* (& (* h(/'& f( ( LADA Cb: N (?!1() 68 ( #(* '(!&i(" (!( O&0(&!: #'9 & :%& # &. /01.& $%& C #0)!P '&j LADA!( & ( ) %() ( \ (( <?:>) B k4'/) C? k(4'/) (?) %%) <J1 6 : # #* C!O0 ()5 k (4'/) (l ( mn ( k(4'/) (=) "g GAD # 4!'&5 GA!('&5 ` %!? D- c +,- ) % #. /0(1 (?) %()!&(B (B&5 o('&!( b!)%(8 <(,'\ & LADA ( )!(? pc( #'9 N!B%1 68 <J1 %( #(!( 6D8 1 #*!& LADA $% 9 l (" %LL/2 (1 %L/I &9!) #'\9 L $%& C.[L%] C 9 GA( %()!&P!?>8 6?: %' _ % LADA. /01 %4 O:(c [] (& %(!' i" r('8 F& 5 i $% 9 # #%1 L $%& ( \ ((.C( 0& #'n #?) _ ( %( J'( ( 1 C 9 K) l,1 ( LADA #(,'( >\ 6) L $%(& C( LADA O:(c 1 5 C! : #(* (" #(?) 5!P[%(* s'd(& G(/ # K) ( #( 9 '0 LADA # B&5!?8,' '

3 $# ( ). GAD 65 u'&5 ) GA CB& &9 {\ f( (((((. ( (A& (J& ( (GADA) (((((( # C? u? D- ((((( ) +,- J& HHM GAD u'&5 (((J& 2L ((((" C?(q ( O.&9 N =1 GAD u'&5 (B&5 ]( } #(* J& 2L "! : #( %(DA) C( # :. /01 ) Z ) M <) 2L " & %D& ) :%& J' HHM (" &(9 (& %\ LADA % # %*n) J& &(9 h%(k) L $%(& C( %( #( (O #=) " k4'/)!"~ IDF 6)(9 o( <(J') (?) f ] :%').9 [3] (Iu/ml) GAD! () GAD ATP III [X] WHO [I] C( #(,'( :C % %) # % ( '(9& %(\ (8 () 9. /01 1 #(&" #( ( ]( OGTT #' ] 23 G M!&) :%& # TLGS TLGS #?:>) #?:>) #&" # #(,'(!4D8 #= #*.C. /01 ' ) #(* '9 C q mr) C C( #,'. B&5!) #&%& _ %(%) (B1 E : 8 #?:>) 2 #4) B'& 1 #( (?) f(.&9 mn #?:>) %D& J& SHL :&9./0) J& MLX 6* #?:>).@%( J& HM J& L TLGS #(?:>) C(9 & #(&%& J& S %) 10 0 LF;@ M B4 KK GAD E 3F4G H IJ<( % <4

4 ... 6A 3BC 6<D ><? 34& :9: ;678 $ L/2 (IU /m l) G A D LADA EB4 N M GADE 3F4G H IJ<( % N <4 ((((a* u'&5 >! & (J& ( GADA!? D- ' ((" (( 5 e((%1 XX XU ((ƒ(( %(( #* 9 J' ( p% LL X/M!? D- ) % # GADA e%1 XU ƒ f.9 #'" F&!? D- c Solid phase, l # GAD 65 Cat GAD65 Ab Elisa ELA- TLGS L 6 ) t 11 # ((('* '* '9& 8!* %\ *%4" 6K1 C1 :&% u'&5 #?:>) C * J' ELISA.%( S3 ('* #'( (8 ' ) 33 C(!" %&(\ #=( '(9 (' ) (<33U/ml) ()& (B&5 Anti-TPO > ( '(9 & (<H3ng/ml)!(? D- ( ( & Anti-TG > C\ ( DRG International C* (9 # ( % () 4087! O& ) LWIL '* "! K) J'( ( 5 (=) (9 ( " & P)5 %0* `(.(&% *n) B&5 %H % S3/S±2/M B&5!44: f WHO m?) %4K) Z& 5 %& J& GADA GA Anti (Iu/ml) GAD! G((A 6(((8 #((()." ' :!4 ) #( %( ()& c GADA =) e%1.c 9 t(q.% 3WL333 %*n) C * %1 GAD #( %1 _ &% '0 ` %) 3/ M/Lt(( 11 #(( %(()5 (( < (( b1 ( & (J& # y %!.C9 & %!=>) %(1 ( &'(!( l.% %XL C ( (DASP 2003) C(!'&5 OGTT Outlier C?q #4) 1 B&5 O %( # #A '& # p% )& ** B&5.C #'9 %XX!"~ e%1.'0" mn? <DK) &9 #'" F&.% )& c ** B&5 mn Z GADA =)

5 $ ( ). (J& HII (" ]_ LADA $% 9 ( ) (P=3/M) BMI? %S2/I LADA ( (P=3/2) DM2.(trend (P=3/M).%D& <J') & ) ) +([ #'( ("! & LADA %SH/L) '((9 ((8 (23kg/m2 LADA (" #'( %\ 8 O& ).(T 2 DM mg/dl L2M±MU/ mg/dl t((((( 11 #((((( T 2 DM (! ([ e (%1 % (O:.(P=3/) % ( LHU/H±UX/H ((=).%((D& <((J') ((" %((\ k((4'/) T 2 DM %( LLX/U±H3/X LADA 1%1 (((('4* mg/dl LL/L±2M/2mg/dl t( 11 #( 0( GA k4'/) 6) % =) F&.(P=3/3HM),'D) LADA %2S/S p&%d& P " %\ N((((((8 ( #(*!:( (&% %\ 0 # ( (((((=).(P=3/3I) %(( %H3/ T 2 DM ((((((" mmhg t( 11 #( (((("!:%'( %\ ((((0.(P=3/32) %(((( 22/U±LL/H mmhg LH±M/M %(\!:%'( 0( LADA (" ( %H/M %2S/X T 2 DM (" %() ( #*!: '9 ( ]( $% 9 F& ".(P=3/32) %.(L ) &% P k4'/) k?1 t (" GAD ( u('&5 `( #(& ) #(*5 # #%1 ( ( f( (" ( % 2 IU / ml &(9 N (=1 (J& M #(%A) # ( ) T 2 DM LADA (" ( #4) 1 #* %) %*n() (" ( (&% #'" 8 #=) %) ((((( & (GADA> 2 IU / ml X/M < IU / ml ) %(!( (?) %) B1.&9 #=) i( GADA > #* LADA O& )!? #(* LADA!(" %) SI/2±X/L '9.(P=3/3L) % HS/X±M '9 GADA > ( & %\![ =) BMI '9 F& ('! G!:)! -!? %\ 0 #( #?:>) CK1 J& HHI GADA ` 9 CDa).C9 &!%4>) )5 <8!:) _ ) )5 6 #(!(J * Mean±SD <% #!* k(4'/)!"~ #=).&9 l " <%!( Z(!(* ( b') ( (" %()5 ( t %)5 J' B&5 % )& C?q %()5 J'( (!(J * b') #=)!' )!O:%([ %( #( * na) ()5!( ( ( 4" (1 (=) %() O& ) N'O: (9 J' ] 'O: % )%J& 1. ( 9 l ((" ]( 'O: (?) m (K& /*!( C(B.&(9 u(=41!(?) 3/3H ('d.9 J' H #/& SPSS P )5 6 G~ +,\ #' * j t%r(1 #( N( :%') P0~. ( ( (" #=) #!"~ 6* #& ) #).C 9 5 L 9 ( +,- f(((((.% HS 2WIL t 11 # HII GADA ((`(( (( X/M ((((((( ) ((((J& 2L (((((" ((((( # C?.&9 N =1 (T 2 DM) L $%& C J& HHM LADA ()& +% " ] _ GADA =) e%1 (=) e(%1.c(9 CDa).C 9 5 L %& (Skewness) LADA!O:%[ %D& " GADA t( 11 #( LADA ("!*([ ( #() #& ) (J& # ".% L2/S WU3/S (IH3 2 '0( ) i GADA =) #() GADA %() _ ( s,( '9.0& 32WIH3 (((( c ( #(?:>) %() C(? 6(* LADA $% 9.% (CI%XH :%2/MW%U/2) ((( H/SS ( $%& C HII C(?!( k(4'/) (" LADA $% 9 (./0) %O: ) (P=3/3) % <J') J& P for =3/LH)(*!(& C(?D1 ( C0( *

6 ... 6A 3BC 6<D ><? 34& :9: ;678 $ 3Q < 3F # 3; 3:=5JG R3;Q 6( E:3MP % LO LADA (n=2l) 2 %& '! ( & (n=hhm) #! $ (n=hii) " HL/M ± I/S HS/2 ± /I HS/L ±/M * (-+) *+ 2S/S US/M ±2/L LX/X ±H/ M/ XI/H ± 2/2 3 L/H LH ±2S L2M ±MU 2S/S LH ±U H/M I3 ± LL H/2 / /M LL ±2M 2L ±22 2X ± SL/M UM/S ±L/S LX/X ±S/H / XI/H ±3/H 2H/S / U/M 2 ± 2X LHI ±I3 H3/ 2S ±LL 2S/X IL ±L LM H/S / /U L23 ±H SL ±S3 S3 ± %SL/L UM/2 ±L/H LX/X ±S/H /S XI/H ±3/M 2H/L U/2 23 ±2X LHM ±UX SX 22 ±LL 2S IL ±L LM H/S / /U LLX ±H3 SL ±S3 S3 ± * (%) * (kg) 0 * (kg/m 2 )! &1 # * (%) 25 kg/m 2 0 #! &1 # * (cm) # * (%) '! &3!+ * (%) (&1 $!4 0 5 * (%) 1& * (mg/dl) 6 &3 74 * (mg/dl) + 2 &3 74 * (%) &3 8 9 ** (mmhg) (SBP) :&;+ &3 8 ** (%) SBP? S3mmHg * (mmhg)(dbp) :&+ &3 8 * (%) DBP? X3mmHg * (mg/dl) ; 1 * (mg/dl) <1 -; * (mg/dl) LDL -; * (mg/dl) HDL -; * (%) &3 =& $#>1 ';1 '!?@81 X/S MH/M LH X/L HH 2H/I X/L HH/M 2H/L FBS! A 2hPG! A 2hPG FBS.C 9!'O:?) m K& /! O& ) N'O: f 4" 1 p # 9!) Mean ± SD O& ±=) Latent Autoimmune Diabetes in Adults.(P> 3/3H) %D&?) )5F& LADA L $%& C %) " ) #=) *.(P< 3/3H) %?) )5F& LADA L $%& C %) " ) #=) ** DBP?X3mmHg SBP? S3mmHg

7 $S ( ). 3Q < 3F # TFC TU( V78 W <F X;Q Y< %N LO LADA n=2l 2 %& '! ( & n=hhm #! $ n=hii BBBB" * (%) C:&! <7+ %&6 I2/X I3/M I2/X UX/2 IS/2 IS/S UX/H IS/ IS/2 (8) IDF D! (9) WHO D! (10) ATP III LADA: Latent Autoimmune Diabetes in Adults IDF: International Diabetes Federation WHO: World Health Organization ATP: Adult Treatment Panel.(P> 3/3H) %D&?) )5F& LADA L %( %H/S (%2/MWU/2 ) (B1 B(9 C(? #: ( ua( (1 6() % x( _ ( #?:>).C %) '9 & GADA %Š!-D1!O0)5.% LADA D1)!:%' %\ 0 B1 &! : C(!B( ) x $%& C /01 ( g) '9 F& ) (>) Œ % \ 1i (5 C( =[ b: 5 $% 9 ) #d C %!O0()5! :( N(, (F1 %K& J' %( C( j%(:% 1 f g) # : (B k(4'/) y-() k(4'/) <(?:>) %() ( ( ().[L](& (d #(7!&%"&%" "#A '& ( N '& %1 +% G # `, #?:>) GADA %( ()& (!(4 l # : #(?:>) _ ( ( G (.N (&?1!& #?) ( N: GADA %) %K)C?! ( & %%) %) B1 % b: C (B&5,'( B: #d % %) %( t()& (B&5 C( ('d C9n"!) C #.[] '9 &!&%O! : eq ( ) %() ( \ (( #*?') (B k(4'/) ( C(? LADA!& k(4'/) (?) %%) <J1 6 : # & 9!O0()5 k(4'/) ( l ( mn( D! $%& C %) " ) #=) * (" (! : C?q O ( O ) #) O& LADA ) 1 OGTT B&5 C. 2L.% ) I/HWXU SH/I±2/M t 11 # #?:>) :%(& %(\ C( () J& ] %*n) J& &d!) J' 8 ) J& S d!) J' %( (9 <%( (K-!" mr1 C4 # J& ] _ ( (!=() (C(. /01 Z ) M2).&*!& J' C!&) %(& #(* ( #* 9./0) <,-! ) GADA > 1i d!) J' Z L (XH3 IU / ml ) C9 LADA " J& :%& J' # %DA) OGTT C. /01 C( ) 8 #*!&* J&.% 9 (' 1 i( ( =) & &d!) J' %\ (J& 2L ( ) (' 1 ( ) (F&!? &% GADA IU / IU ml XX / ml LADA (((" ( (8 #* O J& L!'&5 ' 1.( IIM IU / IU ml 2/2 / ml (&d!() J'( %(\ C ).% LH/ U I>! $% (9 #(d 0(& %(K) C(?!(?>=) #?:>) 23 G (!J/) C %) LADA

8 ...6A 3BC 6<D ><? 34& :9: ;678 #K #(d %>&(.% C 'd & UKPDS GADA e( ((%1 %( ((9! () ( (( () #?:( (((>) ] C( % )& (( c 9 ((d <((?:>) t4((c!((o&%o[ ((d Tuomi [ (( p [MWHLS ( b') 6(?1 ( ) ( (?1 b') e%1.[m]c d J' O& ) #&g9%) N: 'd "?1 %) ) #?:>) ( OGTT ` %!? D- d1, C,'(!" %&(\ #= ] _ " N '(& %1 %() ( ().'(9 & ( & C # Anti TPO) e9 NB) 1!'&5 %Š ( t( 11 ( #( N (& & (Anti Tg #( %\ #,' ' 'd (' 1 (=) 68 ( 5(!?( N:( 'd " W ) t 11 #. N 9 #'9 N: GADA 9 %\ =) 'd We%1!d ( %\ '0( LADA!?8 CDa) %). /01 g) ( C e ) #?:>) 'd "! #).% #()!(:'d " O <?:>)!\ #g&5 t(:>) #d A&5 1 [U] C 9 J' J-! ( ( 1 #! 9 C 9 0').C( 0(& (K: O #?:>) _ " (\ #(?) N:! " b1 5 (? \ w1 GADA =) F&!? D- c!? D- ) %)." Fourlanos () <(?:>). (& % e-8 ([ () (& (d J'( XU ADOPT. [HWU L H] & B XX O! C n&g&! h/'&!o&%o[ C!K) CDa) (Skewness)!O:%[ # #%1 #g&5 ~ # ( b1!( %() (#(?) ad GADA e%1 C( (g) '0( =) C #!/'& & n(o 9 h/'& ) y4>) 8 w1 (" ( GADA+ ( (?1 G(d t(%) ( G( #( %' #d!&) 1.(h d!j) G ) `( %( )& k?1 %)!4?!?>8 ` & k(4'/) (=) "g GAD # 4!'&5 GA!('&5 ` %!? D- c +,- ) % #. /0(1 (?) %()!&(B ( o('&!( b!)%8 <,'\ & LADA % GADA $% (9 ADOPT #?:>).[L] & #'9!1J') [M] %( %S/L b: C!:9 g)5 ( :' ( # & GADA $% 9 & Maioli ( y>) W#?:>).[L] d l " %H/ u? (!( #() (& %( %(K)C(? W) #?:>)!' OGTT J' & #'9 () #(?:>) #( x(& & B&5 o'& p& d #?:>) ( & (O #0() %K)C? <?:>).C % #(?:>) #( # D9! - #d C g)5 GADA $% 9 Soriguer-Escofet.[2WH H] & #'9 ) [S] 0(& %2/2 &E h% Ž:!' '& %( C(? () #?:>) #=) [ XX ( GADA ( ) ( % ( (d h(/'&!( ( Barinas- Mitchell.%( (8 (()& dcd9 u7g) #: MH G!"~ (!'( %L/L GADA $% (9 CHS <%(%d (!'( %H/2 (OGTT ( (9./0)) #( XX & ) p[h] 0&!4D8 9 #'\9 5 GADA GA( l ( g ) % [2] (4 Hoorn < (?:>).% ( RIA # (?:>) GADA %( %() 7% [H] Rolandsson #(d 0(& ( OGTT ( (9. /01!' (B&5 #d %9 C8 ) C ) #?:>) #' m,\ #( ( & (&% (d h/'& ) % # XX 6(8 #(d '(9 ( ( J& I = t 11 (} pc( & () #(?:>) ( M33 ( #=) ( (" Hoorn #(?:>) 9 0') #' f.((&% GADA %(() %S/H ((9!(() (( XH <%%d Turner [M] &, Tuomi #((([" % () %3 ( GADA % ( [2] UKPDS! &, #?:>) ) &d l " b: C '9 C #,' #: [ #= #d 9!) 6)9

9 # ( ). LADA (" % g O& )! () ( #(d 9!) d BMI Z F& %() OGTT ( #d C O <?:>) y>) s, )d [2] #(?:>) #[" p[m H] & d! C!d( [LL UM] O <?:>)!\ UKPDS (.& % T 2 DM LADA "! <J1 % (& $(9 y( 8 () %(1!& #d '9 F& (8 GA( ( 9 # g1 = L $%& C #(?:>) 6( #' # g1 '9& %\ #('D:.!) 1!=>) F& # L $%&!' (?1!( ( () #(?:>) P=3/3X #( #%1 () #(?:>). %( %() ( '0 #&%& <(J') %Š C!" %&\ #= Fourlanos %K) O&) <?:>) o'& y>) #* %D& o('& ( Š(1 [LL] Kim %(K) '( [] #:([ #=( (!(O&)!&! 6 _ (.(9!) [U] '4O& Castleden %1 C (= (& %( %() %K) #?) #?:>) L ( $%(& C( %() #= [] Fourlanos '(9& %(\ (8 (=).C( d >) #&".%( (P #?:>) T 2 DM LADA " #' %( #' 8 %) %K) C? #?:>) _ Tuomi ADOPT o('& '(9& (8 %() () & '(9& 8 CHS <%%*.[M M] C ) o'& y>) #(?) 5 () [H]%( T 2 DM '0( LADA (" (" #=) & % ) #?:>) #?) 1 ) (9. /0(1 (1 GADA- GADA+!!4d <% #!8 OGTT LADA HbA1c (=) #(?:>) #( =.& 9 <(J1 x( _ ( #(d [M M S] & d #=) T 2 () ( () #(?:>) #&J') p& #' &?) LADA (" %(\ 0( $% (9.C( 0(& #(?:>) ( y(>) #(d %(D& <(J') ) #?:>) T 2 DM ([ #(d C( (O l (" (B1!(? ADOPT ) 6a) s, ) d!" #=) [M] Tuomi #' y>) ADOPT m,\.[m] T 2 DM %XH k(?1 #( #%1 #d!) F& # % # XU +,-!? D- " #?) ( #((((?:>) ).9!K 8 ).N( (d J'( ELISA l GADA G(((((A %(! l 9 #g&5 # #%1!O0()5 ( l <?:>) GADA (! ='() w(1 () ( (&% C(9 L $%(& C( LADA $% 9 <J1 (D'!( (q (1 (9 l,1!&b > [L] ( %() (!O0()5 k(4'/) ( l l ( 6( y(4>) 8 #=)!&g (!(44: ( "d 6r).[XI] " A!%(\ ( CK( C(8 RBA l #d C % GA(!(,- &'( %( #( (9 >) F& C " l ) [L3] GADA ((F& <((Dw!((!((m((?) C(( C/(( l "(g ( ().C( t()& u(> K)C( 1e 1 5 "g 6 #d C ( (J (q N '(& %1 [L] C ELISA RBA #&%& M33 %XX %XL t 11 #!"~ l $%((& N ((&!(().N ((&!(( GADA ((F& s (? > 8 ( )?1 & GADA GA!O0)5 LADA $% (9 (?1 # (%1 6 (8 < ( b1 t (%) (t( d1 t(%) C g) %\ ) "!) n: " T 2 DM LADA "!J4'/).(9D&!=>) C [ N B&5 #=)! (F& ( (5 #(d C( C - 68 #d!0 d # g1 ) #?:>) o'& # %1!) =[ ) '9 k(?1 s 9 d s, D 8 #d %>& #d C 5 ` #(d C9 F& & C K 68 % )& (d s(g) #d ') % )&?1 Anti 6(a)) N (&!) J' B&5!1= =K1! : 6(8 %() ([ ( & (TSH Anti Tg Ab TPO Ab ( k( ( %() ( si%( C( (-.C h' 68 c!g9!:' >\

10 ...6A 3BC 6<D ><? 34& :9: ;678 #N (?) () ()5 #=)!\ % g) C?(q!( G ( ( ( &!:() (9!' &%9 ( d1 % #?:>) ).%!) #7 68 GADA N '(& %'& x( k4'/) 6) % 0& HOMA-IR!(? :%(& #( C)=)!4.\9 6 : # [ N pn & #=) #?:>) %) " #((=) ((g) (( #(( Anti-TPO `(( '((9 & %() (1e(9!(g #(d W ( 1! %(\ (( WC(( (( ((c N'((! % (\!(4? C?(q ( O #[".N ' & LADA #%A) ) ) C %D& #?:>)!4 m ().Nd O LADA S ( (!(15!:' <J1 0& (g) #(?:>) (.C(!d& ) %K& B&5 ( m,'\ #d GADA `!\ g1 6)d [ #& O #'D: p N '9 & C9 h % (!('&5 (' 1 1i(!& #g&5 0& ) (1 (& #'(9 ( ( #=) '? s % H/S CB&.9!) ` CK 1 #( : s,)(d 6( ) () #(?)!' b: (#(' #( #(%1 C! %\ & %( (B&5 O:(c (P) # :!O0)5! : GADA GA( #d!) F& #. & ( (' #(d ( (1 9!=>)!) 8!&!(9 1 & f g&!& C # 1e.&" =J+K+ XH 8 9 #!1= =K1 - #A '& #:=) N :%') P0~ h%r) # 9!)!'0B O0& #:=) "%&." C\ %dn) d) % 5 < : N) '* N&\ * %\ P01 t1 ) N&\ * - Z%& G P!), N&\ * & 6 4K1 P GAD 65 # 4!'&5 GA B.&!) %(\!:%'( 0 y4>) =) [H] CHS <%%*.%( T 2 DM " 'd ) #?:>) LADA %(\![ =)[ H] CHS <%%* 6a) ) #?:>) '(4d [ % g " m,\(.c(9 T 2 DM ("!& # )5 <Dw 6( #(d (& 0& Tuomi ADOPT ) #' T 2 DM 'B GADA %Š %\![ %(() (?1 y(( 8! ( - ADOPT.[M M] C ( 5 (d) ([ C( ) ()!B%1 68 LADA 6) & %1!) B 8 L k4'/) %0d #(?:>) 5 ( () #?) 6 #' m,'\ $% (9 () #(?:>) m,(\ ( ADOPT #(?:>).9 'd GADA+ " ATP III k?1 x #(d #(&%O& W%(\![ %O: <J1.[M]% (!( 6() (& %1!() W(9 (q%1 i( k(? ( O (- 6(8 6().(9 m,'(\ p(9!() ) %0d! b # & d &' (d (=)!&9%E # #%1 [ (F& #? ) #?:>) T 2 DM LADA #(A '& (d ( ) ( ( +,- #d!) N '(& %'& Fourlanos m,(\ ( ).5 C #!1J') C GADA 9 CDa) '! G!:) C( #(,' <) #?:>) 5.[]N #7 b: <(J1 (= C( 0& l " %\ 8 'd )!=>1 #d C 9 #7 " BMI?) #( %() <,- O %. & ) #?:>) () ( %(\ ((!" %&\ #=.N #'9 &!&g) [ ) #&J') #d C * #(d C( %K) C? <?:>)?) ) #?:>) %() M33 ( (J& ( ([ (*./0()! (' s, ) ( d #(4) C #( ('d (" GADA GA #?:>).C! :(?') %'d C y 8 <%.& 9 #=) "!O0)5 %() 2L (B1 ().C( #'9!CK) ) #?:>) '0( (?1 <%.N ' LADA

11 # ( ). L3M 1. Fourlanos S, Perry C, Stein M, Stankovich J, Harrison L, Colman P. A Clinical Screening Tool Identifies Autoimmune Diabetes in Adults. Diabetes Care 2006; 29: Pozzilli P, Di Mario U. Autoimmune diabetes not requiring insulin at diagnosis (latent autoimmune diabetes of the adult): definition, characterization, and potential prevention. Diabetes Care 2001; 24: Turner R, Stratton I, Horton V, Manley S, Zimmet P, Mackay IR, et al. UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in Type 2 diabetes. Lancet 1997; 350: Monge L, Brunot G, Pinach S, Grassi G, Maghenzani G, Dani F, et al. A clinically oriented approach increases the efficiency of screening for latent autoimmune diabetes in adults (LADA) in a large clinic-based cohort of patients with diabetes onset over 50 years. Diabet Med 2004; 21: Barinas-Mitchell E, Kuller LH, Pietropaolo S, Zhang Y, Henderson T, Pietropaolo M. The prevalence of the 65-Kilodalton Isoform of Glutamic Acid Decarboxylase Autoantibodies by Glucose Tolerance Status in Elderly Patients from the Cardiovascular Health Study. J Clin Endocrinol Metab 2006; 91: Zinman B, Kahn SE, Haffner SM, O Neill MC, Heise MA, Freed MI. Phenotypic characteristics of GAD antibody-positive recently diagnosed patients with type 2 diabetes in North America and Europe. Diabetes 2004; 53: Azizi F, Rahmani M, Emami H, Majid M. Tehran Lipid and Glucose Study (TLGS): Rationale and Design. CVD Prevention 2000; 3: Alberti KG, Zimmet P, Shaw J. The metabolic syndrome: a new worldwide definition. Lancet 2005; 366: Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: & 8 K) C\ B)!&B *. q!'&5 %1 ).B[%) u& %A/& #4 O' L $%&!' ] O0& #4A).B&5 #.UILWUU :(2U 9) 3 p2il 12. Maioli M, Alejandro E, Tonolo G, Gilliam LK, Bekris L, Hampe CS, et al. Study Group for the Genetics of Diabetes in Sardinia: Epitoperestricted 65-kilodalton glutamic acid decarboxylase autoantibodies among new-onset Sardinian type 2 diabetes patients define phenotypes of autoimmune diabetes. J Clin Endocrinol Metab 2004; 89: Ruige JB, Batstra MR, Aanstoot HJ, Bouter LM, Bruining GJ, de Neeling JND, et al. Low prevalence of antibodies to GAD65 in a 50- to 74-year-old general Dutch population. The Hoorn Study. Diabetes Care 1997; 20: Soriguer-Escofet F, Esteva I, Rojo-Martinez G, de Adana SR, Catala M, Merelo MJ, et al. Prevalence of latent autoimmune diabetes of adults (LADA) in Southern Spain. Diabetes Res Clin Pract 2002; 56: Rolandsson O, Hagg E, Hampe C, Sullivan Jr. EP, Nilsson M, Jansson G, et al. Glutamate decarboxylase (GAD65) and tyrosine phosphatase-like protein (IA-2) autoantibodies index in a regional population is related to glucose intolerance and body mass index. Diabetologia 1999; 42: Tuomi T, Carlsson A, Li H, Isomaa B, Miettinen A, Nilsson A, et al. Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes 1999; 48: Castleden HA, Shields B, Bingley PJ, Williams AJK, Sampson M, Walker M, et al. GAD antibodies in probands and their relatives in a cohort clinically selected for Type 2 diabetes. Diabet Med 2006; 23: Bingley PJ, Bonifacio E, Mueller PW. Diabetes Antibody Standardization Program: first assay proficiency evaluation. Diabetes 2003; 52: Mire-Sluis AR, Gaines Das R, Lernmark A. The World Health Organization International Collaborative Study for islet cell antibodies. Diabetologia 2000; 43: Grubin CE, Daniels T, Toivola B, Landin- Olsson M, Hagopian WA, Li L, et al. A novel radioligand binding assay to determine diagnostic accuracy of isoform-specific glutamic acid decarboxylase antibodies in childhood IDDM. Diabetologia 1994; 37: Villalba A, Valdez SN, Iacono RF, Poskus E. Development of 2 alternative enzyme-linked immunosorbent assays for routine screening of glutamic acid decarboxylase autoantibodies. Clin Chim Acta 2007; 376(1-2): Epub 2006 Jul 22.

12 ...6A 3BC 6<D ><? 34& :9: ;678 #$ 22. Kim C, Nam J, Nam J, Park J, Kang E, Ahn C, et al. Clinical and biochemical characteristics of nonobese type 2 diabetic patients with glutamic acid decarboxylase antibody in Korea. Metabolism 2006; 55: